MyOme Presents New Data at ASHG 2022 on an Ethnically-Inclusive Breast Cancer Risk Assessment

Addition of a cross-ancestry polygenic risk score to the standard of care clinical risk predictor tool improved breast cancer risk assessment across multiple ancestries MENLO PARK, Calif., Oct. 27, 2022 /PRNewswire/ -- MyOme, a clinical whole genome platform analysis company, today...

Click to view original post